Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Leukemia 3Hematologic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Cardiotoxicity 2Carcinoma in Situ 2Burkitt Lymphoma 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1

Interventions

Rituximab 4Etoposide 4Cyclophosphamide 4Vincristine 3Prednisone 3Doxorubicin 3liposomal doxorubicin 2varlilumab 1prednylidene 1pomalidomide 1fialuridine 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Primary Effusion × Electrocardiography × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡